CARM (CARISMA Therapeutics) Total Operating Expense: $41.79 Mil (TTM As of Sep. 2025)


What is CARISMA Therapeutics Total Operating Expense?

CARISMA Therapeutics CARM +5.17% Total Operating Expense is $41.79 Mil as of Sep. 2025. The stock has 3 warning signs investors should review.

CARISMA Therapeutics's Total Operating Expense for the three months ended in Sep. 2025 was $1.44 Mil. CARISMA Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2025 was $41.79 Mil.

CARISMA Therapeutics Total Operating Expense Related Terms

CARISMA Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for CARISMA Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics Total Operating Expense Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Total Operating Expense
28.38 40.79 66.00 103.65 81.81

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.53 21.51 13.06 5.78 1.44

CARISMA Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $41.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $41.79 Mil mean?
CARISMA Therapeutics (CARM) has a Total Operating Expense of $41.79 Mil as of Sep. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on CARISMA Therapeutics and its competitors.
Is CARISMA Therapeutics' Total Operating Expense too high?
CARISMA Therapeutics' current Total Operating Expense is $41.79 Mil.
How does CARISMA Therapeutics' Total Operating Expense compare to SCPX and CYTOF?
CARISMA Therapeutics' Total Operating Expense of $41.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on CARISMA Therapeutics and its competitors. CARISMA Therapeutics's current Total Operating Expense is $41.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.01 — trading 99.8% below its estimated fair value. The current Total Operating Expense is $41.79 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current Total Operating Expense is $41.79 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARISMA Therapeutics Business Description

Address 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.